Lung Cancer Research Review, Issue 18

In this issue:

Pembrolizumab vs chemotherapy in PD-L1-positive NSCLC
Osimertinib active in EGFR T790M positive NSCLC
Advantages with IMRT vs 3D-CRT in locally-advanced NSCLC
Changes in depression symptoms influence lung cancer survival
Biomarker-driven treatment focusing on KRAS-mutated disease
Aggressive local consolidative therapy in oligometastatic NSCLC
Brigatinib in advanced ALK-rearranged NSCLC
Tolerability-guided dose adjustment of afatinib
Prognostic value of tumour-infiltrating lymphocytes
Alectinib promising in crizotinib-refractory ALK-positive NSCLC

Please login below to download this issue (PDF)